About: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
Creator	Antonio, · Sabatino, Di Fiorina, Paolo Galli, · Solerte, Sebastiano
Source	Medline; PMC
abstract	AIMS: SARS–CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19. METHODS: Virus binds to the cell surface receptor ACE2; indeed, recent evidences suggested that SARS–CoV-2 may be using as co-receptor, when entering the cells, the same one used by MERS–Co-V, namely the DPP4/CD26 receptor. The aforementioned observation underlined that mechanism of cell entry is supposedly similar among different coronavirus, that the co-expression of ACE2 and DPP4/CD26 could identify those cells targeted by different human coronaviruses and that clinical complications may be similar. RESULTS: The DPP4 family/system was implicated in various physiological processes and diseases of the immune system, and DPP4/CD26 is variously expressed on epithelia and endothelia of the systemic vasculature, lung, kidney, small intestine and heart. In particular, DPP4 distribution in the human respiratory tract may facilitate the entrance of the virus into the airway tract itself and could contribute to the development of cytokine storm and immunopathology in causing fatal COVID-19 pneumonia. CONCLUSIONS: The use of DPP4 inhibitors, such as gliptins, in patients with COVID-19 with, or even without, type 2 diabetes, may offer a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1007/s00592-020-01539-z
bibo:pmid	32506195
has license	no-cc
sha1sum (hex)	3bb381a4d641c06aef82857dc12cf57f6df47a2a
schema:url	https://doi.org/10.1007/s00592-020-01539-z
resource representing a document's title	Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
has PubMed Central identifier	PMC7275134
has PubMed identifier	32506195
schema:publication	Acta Diabetol
resource representing a document's body	covid:3bb381a4d641c06aef82857dc12cf57f6df47a2a#body_text
is schema:about of	named entity 'cytotoxic' named entity 'kidney' named entity 'respiratory tract' named entity 'SARS-CoV-2' named entity 'DPP4' named entity 'immune system' named entity 'causing' named entity 'ACE2' named entity 'high' named entity 'immunopathology' named entity 'processes' named entity 'DPP4' named entity 'pneumonia' named entity 'small intestine' named entity 'physiological processes' named entity 'human respiratory tract' named entity 'systemic vasculature' named entity 'COVID-19' named entity 'endothelia' named entity 'SARS-CoV-2' named entity 'DPP4' named entity 'alanine' named entity 'dipeptidyl peptidase-4' named entity 'SARS-CoV' named entity 'diabetic patients' named entity 'interstitium' named entity 'CD26' named entity 'Middle East respiratory syndrome coronavirus' named entity 'angiotensin-converting enzyme 2' named entity 'COVID' named entity 'plasma' named entity 'endothelial cells' named entity 'edema' named entity 'spleen' named entity 'Coronaviruses' named entity 'data analysis' named entity 'lung' named entity 'SARS-CoV-2' named entity 'N-terminal' named entity 'CD26' named entity 'CD26' named entity 'dipeptides' named entity 'immunopathology' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'cytokine storm' named entity 'SARS-CoV-2' named entity 'intracellular signals' named entity 'glycoprotein' named entity 'DPP4' named entity 'ACE2' named entity 'Dipeptidyl peptidase-4' named entity 'ischemic' named entity 'thrombotic' named entity 'DPP4' named entity 'SARS-CoV' named entity 'gliptins' named entity 'small intestine' named entity 'proinflammatory cytokines' named entity 'Milan' named entity 'co-expression' named entity 'diabetic patients' named entity 'heart failure' named entity 'kidney' named entity 'pathogenesis' named entity 'endothelial' named entity 'animal rights' named entity 'N-glycan' named entity 'DPP4' named entity 'N-terminus' named entity 'Europe' named entity 'coronavirus 2019' named entity 'DPP4' named entity 'gliptins' named entity 'ACE2' named entity 'San Matteo Hospital' named entity 'SBS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software